News | July 05, 2023
CARE reaffirms A+ rating to IOL Chemicals and Pharmaceuticals
The 'A+' rating reflects IOL's robust business model, diversified product portfolio
The 'A+' rating reflects IOL's robust business model, diversified product portfolio
Cyanocobalamin Nasal Spray (RLD Nascobal) had estimated annual sales of USD 69 million in the U.S. (IQVIA MAT Mar 2023)
The zero-observation outcome reflects the company's robust quality management systems and commitment to excellence in its operations.
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
Alembic has a cumulative total of 184 ANDA approvals (159 final approvals and 25 tentative approvals) from USFDA.
The VITA-FAST tokens have been met with overwhelming interest
Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024
Granules India sponsored an initiative to ignite a drug-free revolution and contribute towards an empowered society
Oncodesign Services and ImaginAb sign a Preclinical License and Supply Agreement
Currently there are no vaccines approved anywhere in the world for gonorrhoea, and antimicrobial resistance to existing treatments is increasing
Subscribe To Our Newsletter & Stay Updated
